intermediateolanzapinemetabolic syndromeantipsychoticmonitoringschizophrenia
A 42-year-old man with schizophrenia has been stable on olanzapine 20 mg nightly for 18 months. At his quarterly visit, his fasting glucose is 118 mg/dL (previously 92), triglycerides are 280 mg/dL (previously 160), waist circumference is 42 inches (previously 38), and blood pressure is 138/88 mmHg. His BMI has increased from 28 to 33 over the past year. He reports feeling well psychiatrically with no psychotic symptoms. Which of the following reflects the most comprehensive and appropriate clinical response?